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An unusual case of sarcoidosis in an adult patient with
sickle cell disease: Management with methotrexate and
low dose of steroid
To the editor: Sarcoidosis is a multisystem disease, which pathogenesis is
still only partially known. The prevalence of sarcoidosis is largely different
depending on race and ethnicity [1]. The association of sarcoidosis and
sickle cell disease (SCD) has been reported in few cases [2]. In June
2011, a 52-year-old-man with sickle/b-thalassemia in a care of our service
since 2005 presented with a 2 week history of cough and non-specific
chest discomfort, without fever or typical SCD-related. He had been
treated with hydroxyurea (20 mg/kg/day) for the past 6 years following an
acute chest syndrome; during this time he had sporadic episodes of
headache with a brain magnetic resonance documenting silent infarction
in the left parietal brain area. The patient was clinically evaluated and bio-
chemistry and hematological parameters were performed. Hematocrit was
37%, hemoglobin levels were 11.7 g/dL, reticulocytes were 350,000/lL,
lactate dehydrogenase was 708 U/L, and both transaminases were
slightly increased (aspartate transaminase, AST 64 U/L; alanine transami-
nase, ALT: 55 U/L). The pulmonary vital capacity was significantly
reduced (<60%). The X-ray chest documented two lower zone pulmonary
opacities, while a chest and abdomen computed tomography (CT) scan
revealed lower zone pulmonary infiltrates and multiple lymph nodes in the
superior mediastinum, two lymph nodes in parathracheal area, few lymph
nodes at the celiac trunk and in the inguinal area. The map of enlarged
lymph nodes was confirmed by positron emission tomography (PET)-CT.
The histology of the removed PET-CT positive inguinal lymph node was
consistent with angiolymphoma. Some of the mediastinal lymph nodes
were removed with mediastinoscopy. The mediastinal lymph node biopsy
showed the presence of partially confluent, non-caseating granulomas
with focal associated deposition of fibrous tissue. The lymph node biopsy
was consistent with sarcoidosis (fungal and tuberculosis cultures were
negative). Hydroxyurea was stopped and erythrocytapheresis was initiated
to prevent severe SCD clinical manifestations [3,4]. Although glucocorti-
coids are the most commonly used therapeutic agent for sarcoidosis,
SCD patients incur the risk of developing severe sickle cell related clinical
manifestation during treatment with steroids [5]. In sarcoidosis, methotrex-
ate (MTX) has been proposed as a standard second-line agent in patients
that cannot use or do not respond to steroids [6]. Limited data on MTX
and SCD are present in the literature. In a group of SCD patients with
rheumatic disorders treated with MTX, increased vaso-occlusive crisis has
been reported [5]. Therefore, the patient was treated with a low dose of
prednisone (25 mg/day) associated with MTX (7.5 mg weekly and folic
acid 5 mg/week). After 6 months of treatment, the chest CT demonstrated
a reduction in size of both lung infiltrates and mediastinal lymph nodes.
Neither sickle cell related acute events nor significant changes in transa-
minases levels were reported in a 10-month follow-up. This is the first
reported case of sarcoidosis in SCD patient treated with low dose gluco-
corticoid and MTX, in which erythrocytapheresis has been used in clinical
management of a SCD patient to prevent SCD acute manifestations.
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